iZafe Group AB ("iZafe Group"), in collaboration with Atea Sverige AB, is proud to announce their presence at Vitalis 2024, the Nordic region's leading venue for the future of health, care, and welfare. As part of Atea Sverige's extensive exhibition, iZafe Group will be showcased in Atea's booth. The fair will take place at the Swedish Exhibition & Congress Centre in Gothenburg from May 14 to May 16.

Vitalis is an arena where e-health, welfare technology, and innovation are in focus. It brings together leading industry players to exchange knowledge about challenges and solutions and to discuss how visions can be transformed into reality. As a prominent player in the healthcare technology field, iZafe Group will showcase its latest advancements and solutions, including the innovative medication robot, Dosell. Their presence at the fair also marks an important milestone following the procurement win to supply Dosell to the Västra Götaland Region (VGR). This underscores iZafe Group's commitment to enhancing the independence and safety of care recipients through advanced technology.

During Vitalis, the iZafe team looks forward to demonstrating how Dosell can play a crucial role in improving the quality of life for care recipients, facilitating healthcare personnel within municipalities, and streamlining medication management. This is part of the company's broader goal to deliver solutions that meet the high demands of today's healthcare and care landscape.

iZafe Group welcomes all visitors to booth B10:10, where the company’s team of experts will be available to discuss how iZafe’s products and services can help improve efficiency and quality in the healthcare sector. For more information about our presence at Vitalis and to register for the event, visit here.

iZafe Group AB ("iZafe Group") is pleased to announce the launch of Dosell version 3.0, the latest edition of our revolutionary medication robot, designed to optimize medication management for users worldwide. In connection with this launch, iZafe Group has also initiated a strategic move of its production to Central Europe in order to be able to scale up the production rate to larger volumes and shorten the delivery distances to existing partners.

The first production run of 1,000 pieces of Dosell version 3.0 has been successfully completed and delivered for the Dutch market, marking the starting point for this new and improved version. With, among other things, a more powerful processor and increased memory capacity, Dosell version 3.0 now enables a unified software platform regardless of geographical location or design of the sachet bag. This represents a significant improvement from previous versions that required extensive customization for each individual country and sachet type. In addition, the new version of Dosell 3.0 introduces several advanced features, including voice and expanded connectivity options, further improving the user experience and accessibility.

"The launch of Dosell version 3.0 is an important milestone for us. The new components in this version not only enable a higher and better performance of existing functions, but also open up a wide range of new and innovative functions in the future. All this, without significantly affect the production cost, thanks to the progress made in the component market since Dosell's first version was developed." Says Anders Segerström, CEO of Zafe Group.

This strategic investment in innovation and product development, together with the relocation of production to Central Europe, positions iZafe Group at the forefront of medical technology solutions. With Dosell version 3.0, iZafe Group can now offer an even more reliable and efficient medicine management solution, making it easier for users worldwide to take the right medicine at the right time.

iZafe Group AB ('iZafe Group') announces that the award decision, which was announced on December 8, 2023, where iZafe Group won the procurement with Helsingborg Municipality for the delivery of Dosell medication dispensers, has now led to the city choosing to cancel the process. This decision is motivated by identified shortcomings in the municipality's procurement documents.

The previous press release was published on December 8, 2023, announcing that iZafe Group had won the procurement with a potential value ranging from 5.5 to 13.8 million SEK for 150–400 Dosell medication dispensers. The award decision was not legally binding.
Despite the interruption, iZafe Group remains optimistic and looks forward to showcasing its expertise once the procurement is resumed.

"It is regrettable that the procurement has been interrupted, but we see this as an opportunity to improve and continue our positive dialogue with Helsingborg Municipality. We are ready to participate again when the procurement is expected to resume in January 2024," says Anders Segerström, CEO of iZafe Group.

iZafe Group's board member, Bosse Johansson, acquired 800,000 Class B shares in the company yesterday, valued at 216,000 SEK (0.27 SEK per share).

The purchase was made yesterday, on November 30th. Bosse Johansson's total shareholding in iZafe now amounts to these 800,000 Class B shares.

"Acquiring shares in iZafe is a step that demonstrates my confidence in the company's direction and potential. I look forward to continuing to contribute to our collective success and supporting the company's development," says Bosse Johansson.

iZafe Group AB ("iZafe Group") announces that the agreement with the Västra Götaland Region (VGR) for the delivery of Dosell medication dispensers has now been concluded. This follows the earlier communication of the award decision and covers 1,800 units, with a maximum of 2,250. The agreement is owned by Atea Sweden AB.

This new agreement, extending until 2025 with the possibility of an extension until 2027, underscores iZafe Group's commitment to enhancing the independence of home care recipients through advanced welfare technology.
The framework agreement includes medication robots from Dosell and has an estimated value of SEK 42–52 million. In addition to VGR, 46 municipalities are connected for call-offs under the agreement.
"By signing this agreement, we take another important step forward in providing efficient solutions for medication management. Our collaboration with Atea Sweden and the newly signed agreement with VGR marks a milestone for us in the healthcare and welfare technology sector," says Anders Segerström, CEO of iZafe Group.
Under the agreement, iZafe Group will supply Dosell medication dispensers to care recipients in VGR, aiming to enhance their independence and safety. "We are proud to contribute to improved healthcare quality and more efficient medication management through our innovative products," Segerström adds.

iZafe Group AB ("iZafe Group") is pleased to announce the successful implementation of their medication robot, Dosell, in Spain. The company has now completed all necessary technical integrations and adjustments required to launch Dosell in the Spanish market after a series of successful integrations. These adaptations encompassed both technical refinements to the Dosell unit itself and the platform, as well as extensive developments and adjustments by our collaboration partner.

As a significant step forward, iZafe Group has now delivered the first 30 Dosell units to Ti-Medi to commence practical testing of the customer journey over the nexts months. This phase of the pilot program will contribute to ensuring a seamless launch and customer experience. Upon successful completion of the testing phase, commercial sales will commence after the turn of the year, in accordance with the previously communicated plan.
"We are thrilled to announce the successful delivery of our cutting-edge pharmaceutical robot, Dosell, to the thriving market of Spain. This marks a significant milestone in our mission to helping patients taking the right medication at the right time in yet another country. We are committed to providing innovative solutions that empower healthcare professionals and improve patient care. This achievement is a testament to the hard work and dedication of our team, and we look forward to making a positive impact on the healthcare landscape in Spain and beyond." Says Anders Segerström, CEO of iZafe Group AB
"We're excited to announce a big change in our business model as we start focusing on serving individual consumers (B2C). This shift is a major milestone for us, and we know there's a lot of work to do. We're staying dedicated to working closely with our trusted pharmacy partners to make sure our pilot program gets the attention and resources it needs. We're confident that by leveraging our current partnerships and industry knowledge, this initiative will be a valuable learning experience. We're teaming up with iZafe to bring innovative solutions to the B2C market in the MDS industry." Rafa Tibau, CIO of Ti-Medi.

iZafe Group's CEO, Anders Segerström, has today acquired an additional 208,333 B-shares in the company. The transaction was completed at a total value of 50,000 SEK, equivalent to 0.24 SEK per share. With this latest purchase, Anders Segerström now holds a total of 1,598,773 B-shares in iZafe Group.

"It is with pleasure and belief that I increase my ownership stake in iZafe Group. This decision reflects my full confidence in our dedicated team and our future potential. Today, we stand on a strong foundation to collectively continue working hard towards creating a successful future for our shareholders, the company, individuals who require multiple medications, society, and healthcare." says Anders Segerström, CEO iZafe Group AB.

iZafe group AB (publ.) is proud to present an exciting new development in the company's identity and expression. With the goal of further strengthening its presence on the international scene, the company is today launching an updated logo and design, in parallel with the launch of a new website that is in both Swedish and English.

iZafe's current logo and color language were developed when the company focused on both safety and health. iZafe implements this change to better reflect the company's current vision and direction and make it easier for owners and other stakeholders to get a correct and comprehensive picture of where the company stands and is headed.
The new design captures the company's dedication to developing digital products to ensure the right medication at the right time, while standing as a symbol of precision and care for each individual patient.
At the center of the new logo is a subtle pill shape, surrounded by rings reminiscent of fingerprints. This design highlights the uniqueness of the individual and the company's focus on patients. The clean and elegant lines radiate efficiency and streamlined operations, demonstrating the simplicity and convenience of the automated products and services. The rings expand from the pill like ripples on the water and symbolize change and transformation. The technological elements are emphasized by node-like line endings.
The new logo is complemented by a clean and modern typography, which harmoniously enhances the simplicity and style of the design.
In connection with iZafe receiving great interest internationally, the website is being launched in both Swedish and English and is designed to give visitors a deeper insight into the company's innovative work and commitment to patient safety and medical adherence.
"With the new logo and design, we are taking a powerful step into the future. We are strengthening our commitment to being the leading player in digital services for correct medication. This change reflects our determination to streamline our focus and corporate profile towards our core business. We are ready to shape a new era where we become the natural partner for healthcare companies globally, and our goal is clear – to help people stay healthy and live longer in their own homes.” says Anders Segerström, CEO iZafe Group.

Today, the Chairman of iZafe Group, Björn Rosengren, has acquired 500,000 Class B shares in the company, valued at 110,000 SEK (0.22 SEK per share.

In addition to today's transaction, Björn Rosengren also acquired 50,000 A-shares last week. Björn Rosengren now holds a total of 2,960,319 B-shares and 50,000 A-shares.

"I am pleased to increase my ownership in iZafe Group, which reflects my belief in the company's vision and potential," says Björn Rosengren. "These acquisitions demonstrate my continued commitment to supporting iZafe Group's strategic goals and creating value for its shareholders."

iZafe Group AB ("iZafe Group") announces today that the company has successfully completed all necessary technical integrations and adaptations to launch its groundbreaking medication robot, Dosell, in the Dutch market. These adaptations have included both technical adjustments in the Dosell device and platform, as well as extensive developments and customizations from our partner.

As a significant step forward, iZafe Group will now deliver 50 Dosell units to test the new customer journey in practice for one month. This phase of the pilot program will contribute to ensuring a smooth launch and customer experience. Following successful testing, the remaining 1,000 units will be delivered gradually throughout the rest of the year, according to the previously communicated plan.

"We are delighted to be part of this collaboration with iZafe Group for the launch of Dosell in the Dutch market. Dosell offers a groundbreaking digital medication robot that complements our existing portfolio of connected healthcare services. We are confident that Dosell will provide a reliable and secure alternative for the medication needs of our healthcare and alarm center clients in the Netherlands. Together, we can fulfill our shared mission of promoting independence and security in the simplest, safest, and most cost-effective way," says Martijn Van Bree, CEO of IVE Ventures.

"We are very pleased to have completed the technical integrations and adaptations for the launch of Dosell in the Dutch market. This marks a significant milestone for us and opens doors to a market known for its commitment to medication in pouches. The selection of Dosell by IVE Ventures after careful evaluation of competitors confirms the great potential of our product on the international stage. We look forward to collaborating with IVE and enabling a safe and efficient medication experience for their clients," says Anders Segerström, CEO of iZafe Group AB.

Webbdesign av Comlog Webbyrå Stockholm